Impact of Clostridium difficile on inflammatory bowel disease

References

• Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N. Engl. J. Med.298, 531–534 (1978).
   PubMed Web of Science ®Google Scholar
• Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am. J. Infect. Control37, 263–270 (2009).
   PubMed Web of Science ®Google Scholar
• Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect.12(Suppl. 6), 2–18 (2006).
   PubMed Web of Science ®Google Scholar
• McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg. Infect. Dis.12, 409–415 (2006).
   PubMed Web of Science ®Google Scholar
• Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ171, 466–472 (2004).
   PubMed Web of Science ®Google Scholar
• Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol.7, 526–536 (2009).
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Wertheimer AI. Review of current literature on the economic burden of Clostridium difficile infection. Infect. Control Hosp. Epidemiol.30, 57–66 (2009).
   PubMed Web of Science ®Google Scholar
• Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int. J. Antimicrob. Agents33(Suppl. 1), S42–S45 (2009).
   Web of Science ®Google Scholar
• Ananthakrishnan AN, Issa M, Binion DG. Clostridium difficile and inflammatory bowel disease. Gastroenterol. Clin. North Am.38, 711–728 (2009).
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut57, 205–210 (2008).
   PubMed Web of Science ®Google Scholar
• Issa M, Vijayapal A, Graham MB et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin. Gastroenterol. Hepatol.5, 345–351 (2007).
   PubMed Web of Science ®Google Scholar
• Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin. Gastroenterol. Hepatol.5, 339–344 (2007).
   PubMed Web of Science ®Google Scholar
• Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig. Dis. Sci.55(2), 415–420 (2010).
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol.103, 1443–1450 (2008).
   PubMed Web of Science ®Google Scholar
• Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur. J. Gastroenterol. Hepatol.16, 775–778 (2004).
   PubMed Web of Science ®Google Scholar
• Rolny P, Jarnerot G, Mollby R. Occurrence of Clostridium difficile toxin in inflammatory bowel disease. Scand. J. Gastroenterol.18, 61–64 (1983).
   PubMed Web of Science ®Google Scholar
• Weber P, Koch M, Heizmann WR, Scheurlen M, Jenss H, Hartmann F. Microbic superinfection in relapse of inflammatory bowel disease. J. Clin. Gastroenterol.14, 302–308 (1992).
   PubMed Web of Science ®Google Scholar
• Gryboski JD. Clostridium difficile in inflammatory bowel disease relapse. J. Pediatr. Gastroenterol. Nutr.13, 39–41 (1991).
   PubMed Web of Science ®Google Scholar
• Seaver RL. Screening for Clostridium difficile in chronic inflammatory bowel disease in relapse. Is it helpful? Is it cost efficient? J. Clin. Gastroenterol.8, 397–400 (1986).
   PubMed Web of Science ®Google Scholar
• Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J. Crohns Colitis.3, 4–7 (2009).
   PubMed Web of Science ®Google Scholar
• Pascarella F, Martinelli M, Miele E, Del Pezzo M, Roscetto E, Staiano A. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J. Pediatr.154, 854–858 (2009).
   PubMed Web of Science ®Google Scholar
• Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N. Engl. J. Med.346, 334–339 (2002).
   PubMed Web of Science ®Google Scholar
• Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin. Infect. Dis.46(Suppl. 1), S12–S18 (2008).
   PubMed Web of Science ®Google Scholar
• Kelly CP. A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA301, 954–962 (2009).
   PubMed Web of Science ®Google Scholar
• McFarland LV. Renewed interest in a difficult disease: Clostridium difficile infections – epidemiology and current treatment strategies. Curr. Opin. Gastroenterol.25, 24–35 (2009).
   PubMed Web of Science ®Google Scholar
• Gaynes R, Rimland D, Killum E et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin. Infect. Dis.38, 640–645 (2004).
   PubMed Web of Science ®Google Scholar
• Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis.41, 1254–1260 (2005).
   PubMed Web of Science ®Google Scholar
• Monaghan T, Boswell T, Mahida YR. Recent advances in Clostridium difficile-associated disease. Gut57, 850–860 (2008).
   PubMed Web of Science ®Google Scholar
• Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA294, 2989–2995 (2005).
   PubMed Web of Science ®Google Scholar
• Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ171, 33–38 (2004).
   PubMed Web of Science ®Google Scholar
• Arif M, Weber LR, Knox JF et al. Patterns of proton pump inhibitor use in inflammatory bowel disease and concomitant risk of Clostridium difficile infection. Gastroenterology132, A513 (2007).
   Google Scholar
• Kelly CP, LaMont JT. Clostridium difficile infection. Annu. Rev. Med.49, 375–390 (1998).
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm. Bowel Dis.15, 182–189 (2009).
   PubMed Web of Science ®Google Scholar
• Sonnenberg A, Richardson PA, Abraham NS. Hospitalizations for inflammatory bowel disease among US military veterans 1975–2006. Dig. Dis. Sci.54, 1740–1745 (2009).
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Trends in ambulatory and emergency room visits for inflammatory bowel diseases in the United States: 1994–2005. Am. J. Gastroenterol. (2009).
   Google Scholar
• Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med.342, 390–397 (2000).
   PubMed Web of Science ®Google Scholar
• Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet357, 189–193 (2001).
   PubMed Web of Science ®Google Scholar
• Lowy I, Molrine DC, Leav BA et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med.362, 197–205 (2010).
   PubMed Web of Science ®Google Scholar
• Simms LA, Doecke JD, Walsh MD, Huang N, Fowler EV, Radford-Smith GL. Reduced α-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn’s disease. Gut57, 903–910 (2008).
   PubMed Web of Science ®Google Scholar
• Shen BO, Jiang ZD, Fazio VW et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin. Gastroenterol. Hepatol.6, 782–788 (2008).
   PubMed Web of Science ®Google Scholar
• Lundeen SJ, Otterson MF, Binion DG, Carman ET, Peppard WJ. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J. Gastrointest. Surg.11, 138–142 (2007).
   PubMed Web of Science ®Google Scholar
• Powell N, Jung SE, Krishnan B. Clostridium difficile infection and inflammatory bowel disease: a marker for disease extent? Gut57, 1183–1184 (2008).
   PubMed Web of Science ®Google Scholar
• Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev.18, 247–263 (2005).
   PubMed Web of Science ®Google Scholar
• Rupnik M, Grabnar M, Geric B. Binary toxin producing Clostridium difficile strains. Anaerobe9, 289–294 (2003).
   PubMed Web of Science ®Google Scholar
• Giesemann T, Egerer M, Jank T, Aktories K. Processing of Clostridium difficile toxins. J. Med. Microbiol.57, 690–696 (2008).
   PubMed Web of Science ®Google Scholar
• Jank T, Giesemann T, Aktories K. Clostridium difficile glucosyltransferase toxin B-essential amino acids for substrate binding. J. Biol. Chem.282, 35222–35231 (2007).
   PubMed Web of Science ®Google Scholar
• Taylor NS, Thorne GM, Bartlett JG. Comparison of two toxins produced by Clostridium difficile. Infect. Immun.34, 1036–1043 (1981).
   PubMed Web of Science ®Google Scholar
• Drudy D, Harnedy N, Fanning S, O’Mahony R, Kyne L. Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland. Clin. Microbiol. Infect.13, 298–304 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson S, Kent SA, O’Leary KJ et al. Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann. Intern. Med.135, 434–438 (2001).
   PubMed Web of Science ®Google Scholar
• Barbut F, Decre D, Lalande V et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J. Med. Microbiol.54, 181–185 (2005).
   PubMed Web of Science ®Google Scholar
• McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin. Infect. Dis.40, 265–272 (2005).
   PubMed Web of Science ®Google Scholar
• Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med.353, 2442–2449 (2005).
   PubMed Web of Science ®Google Scholar
• McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med.353, 2433–2441 (2005).
   PubMed Web of Science ®Google Scholar
• Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet366, 1079–1084 (2005).
   PubMed Web of Science ®Google Scholar
• Goorhuis A, Bakker D, Corver J et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin. Infect. Dis.47, 1162–1170 (2008).
   PubMed Web of Science ®Google Scholar
• Clayton EM, Rea MC, Shanahan F et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am. J. Gastroenterol.104, 1162–1169 (2009).
   PubMed Web of Science ®Google Scholar
• Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA269, 71–75 (1993).
   PubMed Web of Science ®Google Scholar
• Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin. Microbiol. Infect.15, 1053–1066 (2009).
   PubMed Web of Science ®Google Scholar
• Nemat H, Khan R, Ashraf MS et al. Diagnostic value of repeated enzyme immunoassays in Clostridium difficile infection. Am. J. Gastroenterol.104, 2035–2041 (2009).
   PubMed Web of Science ®Google Scholar
• Issa M, Weber LR, Skaros S et al. Decreasing rates of colectomy despite high rates of hospitalization in C. difficile. infection IBD patients: a tertiary referral center experience. Gastroenterology132, A663 (2007).
   Google Scholar
• Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis.5, 549–557 (2005).
   PubMed Web of Science ®Google Scholar
• Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J. Hosp. Infect.70, 298–304 (2008).
   PubMed Web of Science ®Google Scholar
• Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin. Infect. Dis.46(Suppl. 1), S32–S42 (2008).
   PubMed Web of Science ®Google Scholar
• Chiplunker A, Ananthakrishnan AN, Beaulieu DB et al. Long-term impact of clostridium difficile on inflammatory bowel disease. Gastroenterology136(Suppl. 1), S1145 (2009).
   PubMed Web of Science ®Google Scholar
• Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am. J. Gastroenterol.104, 1298–1313 (2009).
   PubMed Web of Science ®Google Scholar
• Leffler DA, Lamont JT. Treatment of Clostridium difficile-associated disease. Gastroenterology136, 1899–1912 (2009).
   PubMed Web of Science ®Google Scholar
• Bartlett JG. New drugs for Clostridium difficile infection. Clin. Infect. Dis.43, 428–431 (2006).
   PubMed Web of Science ®Google Scholar
• Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin. Infect. Dis.40, 1586–1590 (2005).
   PubMed Web of Science ®Google Scholar
• Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis.40, 1591–1597 (2005).
   PubMed Web of Science ®Google Scholar
• Hu MY, Maroo S, Kyne L et al. A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. Clin. Gastroenterol. Hepatol.6, 1354–1360 (2008).
   PubMed Web of Science ®Google Scholar
• Bartlett JG. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin. Infect. Dis.46, 1489–1492 (2008).
   PubMed Web of Science ®Google Scholar
• Pepin J. Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic? Clin. Infect. Dis.46, 1493–1498 (2008).
   PubMed Web of Science ®Google Scholar
• Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am. J. Med.86, 15–19 (1989).
   PubMed Web of Science ®Google Scholar
• Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev.CD004610 (2007).
   Google Scholar
• Bauer MP, van Dissel JT, Kuijper EJ. Clostridium difficile: controversies and approaches to management. Curr. Opin. Infect. Dis.22, 517–524 (2009).
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis.45, 302–307 (2007).
   PubMed Web of Science ®Google Scholar
• Louie T. Results of a Phase III trial comparing tolveamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD). Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA, ASM Press (2007) (Abstract k-4259).
   Google Scholar
• Ben-Horin S, Margalit M, Bossuyt P et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin. Gastroenterol. Hepatol.7, 981–987 (2009).
   PubMed Web of Science ®Google Scholar
• Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst. Rev.CD004611 (2008).
   Google Scholar
• Jiang ZD, Dupont HL, La Rocco M, Garey KW. WITHDRAWN: In vitro activity of rifaximin and rifampin against clinical isolates of Clostridium difficile in Houston, Texas, Anaerobe DOI: 10.1016/j.anaerobe.2008.12.008 (2009) (Epub ahead of print).
   Google Scholar
• Bobak DA. Rifaximin to Treat recurrent Clostridium difficile colitis. Curr. Infect. Dis. Rep.10, 90–91 (2008).
   Google Scholar
• Garey KW, Jiang ZD, Bellard A, Dupont HL. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J. Clin. Gastroenterol.43(1), 91–93 (2009).
   PubMed Web of Science ®Google Scholar
• Issa M, Weber LR, Brandenburg H et al. Rifaximin and treatment of recurrent Clostridium difficile infection in patients with inflammatory bowel disease. Am. J. Gastroenterol.101, S469 (2006).
   Google Scholar
• Chan S, Kelly M, Helme S, Gossage J, Modarai B, Forshaw M. Outcomes following colectomy for Clostridium difficile colitis. Int. J. Surg.7, 78–81 (2009).
   PubMed Web of Science ®Google Scholar
• Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for Clostridium difficile colitis. Dis. Colon. Rectum47, 1620–1626 (2004).
   PubMed Web of Science ®Google Scholar
• Hall JF, Berger D. Outcome of colectomy for Clostridium difficile colitis: a plea for early surgical management. Am. J. Surg.196, 384–388 (2008).
   PubMed Web of Science ®Google Scholar
• Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J. Infect.58, 403–410 (2009).
   PubMed Web of Science ®Google Scholar
• McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol.97, 1769–1775 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis.44, 846–848 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe15, 290–291 (2009).
   PubMed Web of Science ®Google Scholar
• McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol.101, 812–822 (2006).
   PubMed Web of Science ®Google Scholar
• Salcedo J, Keates S, Pothoulakis C et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut41, 366–370 (1997).
   PubMed Web of Science ®Google Scholar
• McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis. Colon Rectum49, 640–645 (2006).
   PubMed Web of Science ®Google Scholar
• Abougergi MS, Broor A, Cui W, Jaar BG. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J. Hosp. Med.5, E1–E9 (2010).
   PubMedGoogle Scholar
• Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection – an unusual cause of refractory pouchitis: report of a case. Dis. Colon Rectum46, 267–270 (2003).
   PubMed Web of Science ®Google Scholar
• Shen B, Goldblum JR, Hull TL, Remzi FH, Bennett AE, Fazio VW. Clostridium difficile-associated pouchitis. Dig. Dis. Sci.51, 2361–2364 (2006).
   PubMed Web of Science ®Google Scholar
• Tsironi E, Irving PM, Feakins RM, Rampton DS. ‘Diversion’ colitis caused by Clostridium difficile infection: report of a case. Dis. Colon Rectum49, 1074–1077 (2006).
   PubMed Web of Science ®Google Scholar
• Miller DL, Sedlack JD, Holt RW. Perforation complicating rifampin-associated pseudomembranous enteritis. Arch. Surg.124, 1082 (1989).
   PubMedGoogle Scholar
• Vesoulis Z, Williams G, Matthews B. Pseudomembranous enteritis after proctocolectomy: report of a case. Dis. Colon Rectum43, 551–554 (2000).
   PubMed Web of Science ®Google Scholar
• Yee HF Jr, Brown RS Jr, Ostroff JW. Fatal Clostridium difficile enteritis after total abdominal colectomy. J. Clin. Gastroenterol.22, 45–47 (1996).
   PubMed Web of Science ®Google Scholar
• Causey MW, Spencer MP, Steele SR. Clostridium difficile enteritis after colectomy. Am. Surg.75, 1203–1206 (2009).
   PubMed Web of Science ®Google Scholar
• Lavallee C, Laufer B, Pepin J, Mitchell A, Dube S, Labbe AC. Fatal Clostridium difficile enteritis caused by the BI/NAP1/027 strain: a case series of ileal C. difficile infections. Clin. Microbiol. Infect.15, 1093–1099 (2009).
   PubMed Web of Science ®Google Scholar
• Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin. Infect. Dis.46(Suppl. 1), S43–S49 (2008).
   PubMed Web of Science ®Google Scholar
• Oughton MT, Loo VG, Dendukuri N, Fenn S, Libman MD. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect. Control Hosp. Epidemiol.30, 939–944 (2009).
   PubMed Web of Science ®Google Scholar
• Vonberg RP, Kuijper EJ, Wilcox MH et al. Infection control measures to limit the spread of Clostridium difficile. Clin. Microbiol. Infect.14(Suppl. 5), 2–20 (2008).
   PubMed Web of Science ®Google Scholar